Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

473 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-18

Study Completion Date

2020-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test every year from the second year to the fifth year after the ending of peginterferon alfa treatment, and long-term benefit of interferon treatment will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

NCT06707922

Chronic Hepatitis B

ENROLLING_BY_INVITATION NA

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

NCT02745704

Chronic Hepatitis B

UNKNOWN PHASE4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

NCT02838810

Chronic Hepatitis B

UNKNOWN PHASE4

Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B

NCT01311947

Hepatitis B, Chronic

COMPLETED

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

NCT04846491

Chronic Hepatitis B

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

peginterferon alfa 2b

Peginterferon Alfa-2B

Intervention Type DRUG

pre-received standard peginterferon alfa-2b therapy

peginterferon alfa 2a

Peginterferon Alfa-2A

Intervention Type DRUG

pre-received standard peginterferon alfa-2a therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peginterferon Alfa-2B

pre-received standard peginterferon alfa-2b therapy

Intervention Type DRUG

Peginterferon Alfa-2A

pre-received standard peginterferon alfa-2a therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pegberon pegasys

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Understand and sign the informed consent form.
* Participated in NCT01760122 study (TB1211IFN) and has received at least 39 doses of peginterferon.

Exclusion Criteria

* Conditions which in the opinion of the investigator should be precluded from the study(e.g., poor compliance).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guiqiang Wang, MD

Role: PRINCIPAL_INVESTIGATOR

Peking University First Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.